Please provide your email address to receive an email when new articles are posted on . The FDA approved the first pulsed field ablation system for the treatment of paroxysmal and persistent AF. The ...
October 28, 2011 (Rockville, Maryland) — For the second day in a row, the Food and Drug Administration's Circulatory System Devices advisory panel debated and discussed data related to another device ...
MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ...
LAUSANNE, Switzerland and SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Argá Medtech today announced positive clinical results from the BURST-AF (NCT05572047) first-in-human trial, demonstrating the ...
A new trial demonstrates that an investigational RF ablation system is more effective than medical management in treating persistent AF, but the trial failed to meet a key predefined safety goal. At ...
The US Food and Drug Administration (FDA) has approved the PulseSelect Pulsed Field Ablation (PFA) System (Medtronic) for the treatment of both paroxysmal and persistent atrial fibrillation (AF), the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results